Evidence map›Paper›PMID 31966351›Full record

ArticleInternational journal of clinical and experimental pathology2017

Recognition of the human antibody-mediated platelet destruction in adult ITP patients by C-reactive protein.

Jia-Qi Pan, Wei Wang, Meng-Lin Wang, Xiao-Yun Li, Jing-Hua Wang, Wei-Wei Zhao, Yao-Yao Tian, Xiu-Shuai Dong, Yong-Fang Jiang

Open access · greenAbstract read
In one paragraph

Article in International journal of clinical and experimental pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Jia-Qi PanDepartment of Hematology, The Second Affiliated Hospital of Harbin Medical University Nangang, Harbin, Heilongjiang, P. R. China.
Wei WangDepartment of Hematology, The Second Affiliated Hospital of Harbin Medical University Nangang, Harbin, Heilongjiang, P. R. China.
Meng-Lin WangDepartment of Hematology, The Second Affiliated Hospital of Harbin Medical University Nangang, Harbin, Heilongjiang, P. R. China.
Xiao-Yun LiDepartment of Hematology, The Second Affiliated Hospital of Harbin Medical University Nangang, Harbin, Heilongjiang, P. R. China.
Jing-Hua WangDepartment of Hematology, The Second Affiliated Hospital of Harbin Medical University Nangang, Harbin, Heilongjiang, P. R. China.
Wei-Wei ZhaoDepartment of Hematology, The Second Affiliated Hospital of Harbin Medical University Nangang, Harbin, Heilongjiang, P. R. China.
Yao-Yao TianDepartment of Hematology, The Second Affiliated Hospital of Harbin Medical University Nangang, Harbin, Heilongjiang, P. R. China.
Xiu-Shuai DongDepartment of Hematology, The Second Affiliated Hospital of Harbin Medical University Nangang, Harbin, Heilongjiang, P. R. China.
Yong-Fang JiangDepartment of Hematology, The Second Affiliated Hospital of Harbin Medical University Nangang, Harbin, Heilongjiang, P. R. China.
Harbin Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune thrombocytopenia purpura (ITP) is characterized by destruction of circulating platelets and the presence of antiplatelet IgG antibodies, which opsonize platelets for splenic clearance resulting in low levels of circulating platelets, and the disease severity can be predicted neither by antibody isotype nor by titer, indicating that other factors also play a role. Although the main cause of ITP remains unclear, but its relationship with some infection was demonstrated, including viral or bacterial infections. C-reactive protein (CRP), a member of the pentraxin family, is a major acute-phase protein in humans and is a clinical marker of infection. We aimed to investigate the correlation between the levels of CRP and the presence of antiplatelet IgG antibodies in adults with newly diagnosed ITP. CRP levels and platelet counts were measured in the blood samples from a 60 ITP patient (with confirmed anti-GPIIb/IIIa antibodies), 60 infection patients (all without anti-GPIIb/IIIa antibodies) and 60 normal individuals. The bleeding score, recover time of intravenous immune globulin (IVIg) therapy and the number of megakaryocytes in bone marrow were recorded in ITP patients. The platelet count, bleeding score, recover time of intravenous immune globulin (IVIG) therapy and the number of megakaryocytes in bone marrow and CRP concentrations were compared in ITP group using Spearman's correlation coefficient. We examined the influence of intraperioneal CRP administration on antibody-mediated platelet destruction in mice. There were no statistical differences in gender, age and body mass index among the three groups (P>0.05). Though CRP levels are significantly elevated in ITP patients and infection patients (P<0.05), the platelet count was markedly lower only in ITP patients. We found that CRP was inert toward platelets without antiplatelet antibodies in this study. There are a significant correlation between CRP levels and platelet counts, bleeding severity and the number of megakaryocytes in bone marrow aspiration (r=-0.5079, r=0.5498, r=0.4172, P<0.001, respectively). Moreover, a significant correlation was observed between the recovery time of platelet count and CRP levels (r=-0.5569, P<0.001). In mice, platelet count was lower in Anti-CD41 (0.75 μg)+, CRP (200 μg) group as compared with Anti-CD41 (0.75 μg)+, CRP(-) group and Anti-CD41 (0.75 μg)-, CRP (200 μg) group (P<0.05). In summary, this study indicated that CRP levels are significantly elevated in ITP patients all with confirmed anti-GPIIb/IIIa antibodies, which is able to predict the clinical bleeding severity of ITP patients. The slower CRP levels reduction after IVIg treatment predicted slower platelet count recovery in ITP.

Indexed as

antiplatelet antibodiesC-reactive proteinimmune thrombocytopenic purpura

Identifiers

PMID31966351
PMCPMC6965790
OpenAlexW3026989532

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.